融资

礼来亚洲基金

LILLY ASIA VENTURES

凌科药业管理团队高效的执行能力和国际化视野给我们留下深刻的印象，我们也非常看好自身免疫疾病及肿瘤领域未来巨大的市场空间和未满足的患者需求，期待凌科药业未来用自己的创新能力带来更多突破与成功。

We are deeply impressed by the efficient execution and global vision of Lynk Pharmaceuticals' management team. We are also very optimistic about the future huge market space and the unmet patient needs in the field of autoimmune disease and cancer. We are excited to partner with the Lynk team to accelerate its growth and look forward to more breakthroughs and successes in the future with our innovation capability.

君联资本

LEGEND CAPITAL

自身免疫疾病有巨大未被满足需求，JAK抑制剂在自免用药领域有game changer的潜力，凌科聚焦靶点高选择性和组织特异性的JAK抑制剂，具备做出BIC和FIC的能力，团队以过去在小分子创新药领域的深厚积淀和高效的执行力，将会快速推进创新产品的临床进展和商业化合作。

As there are great demands in autoimmune diseases, JAK inhibitor has the potential to be the game changer. Focused on the highly target-selective and tissue-specific JAK inhibitor, Lynk has the ability to develop BIC and FIC. Besides, clinical progress and business cooperation of innovative therapies will be advanced by virtue of rich experience and efficient execution in the field of small molecule drugs.

德诚资本

德诚资本持续看好全球自身免疫疾病治疗领域的快速发展，并对凌科药业的技术实力和其创始和高管团队在此领域累积多年的经验深具信心。目前，凌科药业已经初步建立起了若干极具特色的靶向药物产品线，并在多个适应症上进入到了临床试验阶段。我们坚信凌科必将从中国扬帆起航，为治愈全球患者做出重要贡献！

DECHENG CAPITAL

Decheng Capital continues to be optimistic about the rapid development of the global autoimmune disease therapeutic field and is confident in the technical strength of Lynk Pharma and the years of experience of its founders and senior management team in this area. At present, Lynk Pharma have established numbers of distinctive targeted drug pipelines and have entered clinical trials in multiple indications. We are confident that Lynk Pharma will set sail from China and help cure patients worldwide!

凯泰资本

凌科药业是我所见过的新药研发效率最高的生物技术公司之一，成立4年时间，有4个自主从头研发的项目进入临床试验阶段。凌科的项目立项也值得称赞，其基于未被满足的医疗需求，建立了平衡了投资回报和失败风险的在研管线组合。同时凌科药业展现了优秀的国际化商务开发的能力，目前已实现了对美国药企的项目授权，以及购买日本顶级科研机构的早期创新资产等多笔交易。

KAITAI CAPITAL

Lynk Pharmaceuticals is one of biotechnology companies I've ever met, which boasts the highest R&D efficiency in novel drugs. Established in four years ago, it has four self-developed drugs entering into clinical trial stage. Moreover, its projects are worthy of credits for the reason that the ongoing pipeline combination balancing between return on investment and risk of failure is established based on unmet medical needs. Besides, Lynk has successfully out-licensed a preclinical candidate to a US company and has bought early-stage innovation of Japan’s top research institute, which embodies its excellent abilities in international business development.